The conclusion of the 2026/27 Community Pharmacy Contractual Framework negotiations represents an important moment for community pharmacy, and one that should give the sector cautious optimism about the direction of travel.
The 10.3% increase in negotiated funding, taking the CPCF settlement to £3.636bn, including the uplift to retained margin and alongside the welcome write-off of up to £239m in historic margin recovery, demonstrates that the Westminster government has at least listened to some of the needs and concerns of community pharmacy.
The counter to that is that the majority of the increased level of retained margin is already in the system from 2025/26, so the network will not feel an immediate cash flow benefit.
Read more: Funding deal for 2026/27 announced
Equally important is the clear commitment from the government and NHS England to work collaboratively with Community Pharmacy England on a programme of reform that looks beyond short-term pressures and towards building a stronger, more clinically integrated future for the sector.
The decision to combine the CPCF and Primary Care Recovery Fund into a single funding pot also signals a more joined-up approach to the future of community pharmacy funding and service delivery.
That commitment creates a real opportunity.
Community pharmacy has long argued that it can and should play a much bigger role in supporting patients, improving access to care and relieving pressure across the wider NHS. We are now beginning to see that ambition reflected more meaningfully within national policy.
Read more: ‘To put it bluntly...’ The industry reacts to the contract news
The expansion of Pharmacy First, the development of the Pharmacy Contraception Service and now the planned introduction of Independent Prescribing all signal a sector that is continuing to evolve clinically and professionally. These developments represent a major opportunity for pharmacy teams to deliver even greater value to patients and local communities.
Repeat
Independent Prescribing has the potential to be transformational, especially if we completely manage repeat prescribing.
The inclusion of infrastructure payments for Independent Prescribing recognises that expanding clinical services requires investment alongside ambition. While many in the sector will rightly question whether the funding goes far enough, it is an important acknowledgement that pharmacy’s clinical future must be properly supported.
Read more: Exclusive - Janet Morrison: Why CPE voted to accept
It supports a future where community pharmacists are increasingly recognised not simply as medicines experts, but as highly accessible clinicians capable of delivering more care closer to home. At a time when pressures across primary care continue to grow, enabling patients to access timely clinical support through their local pharmacy is both sensible and necessary.
Alongside the funding settlement, there are also practical operational improvements that should make a genuine difference to pharmacy teams, including changes to late payment claims and continued focus on protecting colleagues from abuse and violence.
The ability for pharmacies to close for protected staff training time is also a positive and long-overdue recognition of the importance of workforce development and clinical readiness. These are important acknowledgements of the realities teams face on the frontline every day.
Instability
Of course, significant challenges still remain.
The sector continues to face rising operational costs, workforce pressures, and ongoing instability within the medicines supply chain. Many pharmacy owners will rightly feel that, while this settlement provides meaningful progress, it does not yet resolve the long-standing sustainability challenges facing the network.
Similarly, while the introduction of Independent Prescribing is strategically important, there are understandable concerns around whether sufficient investment currently exists to support implementation at the scale and pace envisioned. Delivering high-quality clinical services requires not only ambition, but the right infrastructure, workforce capacity and ongoing sustainable, predictable financial support.
Read more: What the CPE committee said after the deal: ‘Trust does run out...’
The most important shift within this settlement is the recognition that the future cannot simply be about preserving the status quo.
There is now an acceptance across government, NHS England, and the sector itself that reform is going to be needed, not only to secure the long-term sustainability of community pharmacy, but to unlock its full potential within the NHS.
That reform agenda now becomes critical and is one of the main reason Numark is introducing new initiatives, like hub and spoke assembly, that members can access to facilitate a change in operational practice.
The sector has an opportunity to help shape a future funding and contractual model that better reflects the clinical contribution pharmacies make, supports sustainable dispensing and creates the conditions for continued innovation and investment.
Meaningful change
This settlement is not the end of the journey, but it is another step forward.
What matters now is maintaining momentum, strengthening collaboration, and ensuring that the reform programme delivers meaningful long-term change. If that happens, community pharmacy can move beyond simply managing pressures and towards realising the ambitious clinical future the sector has worked towards for many years.
For the first time in many years, there is a sense that community pharmacy is being recognised not simply as part of the NHS infrastructure, but as an essential part of its future. The opportunity is now there to turn that recognition into long-term transformation.
Harry McQuillan is chairman of Numark